Microcirculation and Target Organ Damage in Rheumatic and Skin Diseases

The summary for the Microcirculation and Target Organ Damage in Rheumatic and Skin Diseases grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Microcirculation and Target Organ Damage in Rheumatic and Skin Diseases: The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Eye Institute (NEI) and the Office of Research on Women's Health (ORWH) invite applications to address the mechanisms of end organ damage and alterations in the microcirculation in rheumatic and autoimmune skin diseases. This initiative has three primary purposes. The first purpose is to promote research targeted towards identification and evaluation of cellular, molecular and genetic pathways involved in target organ damage and altered microcirculation in rheumatic and skin diseases. The second purpose of this request for applications is to stimulate and encourage: a) innovative and multidisciplinary basic, translational and clinical studies and b) discovery research projects using new technologies (e.g. microarrays, high throughput sequencing, multi-color flow cytometry, differential display, proteomics, etc). Finally, the purpose of this initiative is to encourage applications as collaborations or as research teams combining interdisciplinary approaches between autoimmune disease researchers and experts in other related scientific fields, such as nephrology and neurology, and vascular biology. The applications in response to this RFA may be for individual research projects (R01) or for exploratory/developmental grants (R21). This RFA solicits basic, translational, and clinical research projects but not epidemiological or clinical treatment projects.